Compare JD.Com Inc (JD) vs Summit Therapeutics Inc (SMMT) Price & Performance

JD.com (JD) trades at $27.09, up 0.22% on the day, with a bullish technical signal despite mixed moving averages. The stock is deeply undervalued with a P/E of 17.9 and P/S of 0.2, supported by strong cash flow and a robust balance sheet with $234 billion in cash. Recent Q2 2026 earnings beat expectations with EPS of $0.93, and the company is progressing on its $2.5 billion acquisition of Ceconomy, pending EU approval (Reuters, 2026-10-02).

The outlook is positive with a consensus price target of $35.86, implying 32% upside, and 70% of analysts rate it a Buy. Risks include revenue declines, regulatory scrutiny from China and the EU, and competitive pressures. The stock's discount to intrinsic value and strong liquidity position offer a compelling opportunity for long-term investors despite near-term headwinds.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.